Read twice and referred to the Committee on Commerce, Science, and Transportation.
This bill directs the National Science Foundation (NSF), in consultation with the Department of Energy and NIST, to stand up a national cloud laboratory network for biotechnology. The Director must produce an implementation plan and convene an advisory board to guide priorities, cybersecurity/biosecurity, data access, and equitable participation.
Data access and IP: liberals push for open/public datasets; conservatives worry about IP capture and prefer protecting proprietary data.
Relative to its intended legislative type, this bill establishes a concrete substantive federal program with clear purposes, phased implementation, named responsible actors, and reporting requirements, but it leaves many operational and fiscal specifics to agency-developed plans.
This bill directs the National Science Foundation (NSF), in consultation with the Department of Energy and NIST, to stand up a national cloud laboratory network for biotechnology.
The Director must produce an implementation plan and convene an advisory board to guide priorities, cybersecurity/biosecurity, data access, and equitable participation.
The program is phased: Phase I creates the network and plan; Phase II funds at least two competitively awarded cloud laboratories (8-year awards) to be operational within 3 years; Phase III funds at least three additional, separate cloud laboratories (6-year awards) beginning within 4 years.
On content alone, the bill is a moderate‑sized, technical infrastructure proposal that incorporates safeguards, consultation, and a sunset—factors that improve prospects. The absence of an explicit appropriation and the subject's biosecurity sensitivity lower its likelihood somewhat; passage therefore depends heavily on subsequent appropriations, interagency coordination, and whether biosecurity concerns can be satisfactorily addressed in committee and floor debate.
Relative to its intended legislative type, this bill establishes a concrete substantive federal program with clear purposes, phased implementation, named responsible actors, and reporting requirements, but it leaves many operational and fiscal specifics to agency-developed plans.
Data access and IP: liberals push for open/public datasets; conservatives worry about IP capture and prefer protecting proprietary data.
These are examples from the analysis, not a ranked list of the most-affected groups.
Data access and IP: liberals push for open/public datasets; conservatives worry about IP capture and prefer protecting proprietary data.
A mainstream progressive would likely view the bill positively as a targeted federal investment to democratize access to advanced biotechnology infrastructure, generate public biological datasets, and expand research capacity at underresourced institutions.
They would welcome provisions that call for equitable access, no-or-low cost access for nonproprietary work, and advisory-board representation for minority-serving institutions.
They would also want stronger, explicit guarantees that data funded by the program remain open and that robust biosecurity, privacy, and ethical safeguards are implemented.
A moderate would likely view the bill as a pragmatic, phased federal effort to fill infrastructure gaps in biotechnology research while trying to coordinate public and private capabilities.
The built-in implementation plan, advisory board, phased grants, and 12-year sunset make it more acceptable to someone who values oversight and measurable outcomes.
The centrist is cautious about potential costs, duplication of privately provided services, and the clarity of access/payment models, and would press for clear metrics, cost estimates, and interagency coordination.
A mainstream conservative would likely be skeptical of expanding federal involvement in operating or funding laboratory infrastructure that may compete with the private sector and impose ongoing costs.
They would be concerned about taxpayer expense, potential crowding-out of private innovation, data/IP rules that disadvantage U.S. firms, and unspecified biosecurity/data-sharing risks.
However, some conservatives might support elements that strengthen national competitiveness in biotech or improve security if safeguards limit data leakage and federal overreach.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, the bill is a moderate‑sized, technical infrastructure proposal that incorporates safeguards, consultation, and a sunset—factors that improve prospects. The absence of an explicit appropriation and the subject's biosecurity sensitivity lower its likelihood somewhat; passage therefore depends heavily on subsequent appropriations, interagency coordination, and whether biosecurity concerns can be satisfactorily addressed in committee and floor debate.
The bill has not accumulated any surfaced votes yet.
Data access and IP: liberals push for open/public datasets; conservatives worry about IP capture and prefer protecting proprietary data.
On content alone, the bill is a moderate‑sized, technical infrastructure proposal that incorporates safeguards, consultation, and a sunset—…
Relative to its intended legislative type, this bill establishes a concrete substantive federal program with clear purposes, phased implementation, named responsible actors, and reporting requirements, but it leaves man…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.